Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Forte Biosciences, Inc.NASDAQ: FBRX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $22.44M rose 39.3% year over year, behind the +71.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at +72.0% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +39.3% toward the trailing-twelve-month pace of +71.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.44M-8.8% QoQ
Last fiscal yearDec 2025
$70.66M+93.2% YoY
LTMMar 2026
$76.99M+71.5% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.3%——
1 year+93.2%——
3-year CAGR+72.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
70.66M USD
Year-over-year change
+93.2%
4-year CAGR
+34.7%

Operating Expenses vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +71.5% is the 3rd highest of 10, against a peer median of -13.7%.
  • Over three fiscal years its annual growth of +72.0% compares with a peer median of +3.6%.
FBRX Competitors
Operating Expenses for FBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$125.25M USD-17.6%-16.6%680.1%
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
FATEFate Therapeutics, Inc.LTM Mar 2026$113.16M USD-11.7%-28.7%1791.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M USD+109.1%+36.8%—
PEPGPepGen Inc.LTM Mar 2026$79.52M USD-27.0%+10.5%—
FBRXForte Biosciences, Inc.LTM Mar 2026$76.99M USD+71.5%+72.0%—
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$37.29M USD-15.8%+17.3%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$36.37M USD-15.3%+7.1%6928.2%
ACTUActuate Therapeutics IncLTM Mar 2026$21.83M USD-8.1%+3.6%—
Peer median (excluding FBRX) —-13.7%+3.6%1791.7%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.